FDA seeks further information on new drug application for veverimer to treat metabolic acidosis in patients with chronic kidney disease

FDA is seeking additional data beyond TRCA-301 and TRCA-301E trials regarding magnitude and durability of treatment effect of this non-absorbed, orally-administered polymer on surrogate marker of serum bicarbonate and applicability of treatment effect to U.S. population.


Biospace Inc.